Deshi-B (02526) and Yongjiang Laboratory signed a strategic cooperation agreement to jointly promote the application of large medical imaging models

Zhitong Finance App News, Deshi-B (02526) announced that the company recently signed a strategic cooperation agreement (agreement) with the Guangxi Zhuang Autonomous Region's key digital intelligence innovation platform Yongjiang Laboratory (Yongjiang Laboratory) to jointly promote the training, optimization, verification and demonstration application of major medical imaging models in Guangxi. The term of cooperation is three years from the date the agreement is signed and effective.

The two sides plan to rely on the regional coordination capabilities of Yongjiang Laboratory to connect with clinical diagnosis, treatment and medical insurance application scenarios of medical institutions at different levels in Guangxi, and combine the Group's iMediMage® medical imaging base model and intelligent software and hardware product capabilities to carry out model training, implementation optimization, multi-center clinical verification, test evaluation and demonstration applications. The two sides also plan to promote relevant solutions to the national medical care and health insurance system based on the application results of Guangxi benchmark model hospitals and regional medical consortia, and explore medical technology cooperation and software and hardware product exports to ASEAN by leveraging Guangxi's location advantages to the Association of Southeast Asian Nations (ASEAN).

The board of directors believes that this cooperation will help the Group rely on multi-level medical scenarios in Guangxi, enrich model training and clinical verification conditions, enhance scenario adaptation and implementation service capabilities, and accelerate the large-scale application and commercialization of the Group's large-scale medical imaging models. Guangxi's demonstration application can also provide a reference for national promotion, and combine its location with ASEAN to create conditions for the Group to expand overseas markets and promote the export of smart medical solutions in China. This cooperation conforms to the overall interests of the Company and shareholders.